Last reviewed · How we verify

Galderma Brasil Ltda. — Portfolio Competitive Intelligence Brief

Galderma Brasil Ltda. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Adapalene-BPO Gel Adapalene-BPO Gel marketed Retinoid + peroxide combination Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Derm Research, PLLC · 1 shared drug class
  2. GWT-TUD GmbH · 1 shared drug class
  3. Galderma R&D · 1 shared drug class
  4. Padagis LLC · 1 shared drug class
  5. Stiefel, a GSK Company · 1 shared drug class
  6. Wake Forest University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Galderma Brasil Ltda.:

Cite this brief

Drug Landscape (2026). Galderma Brasil Ltda. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/galderma-brasil-ltda. Accessed 2026-05-17.

Related